What is GT Biopharma, Inc. (GTBP)?

GT Biopharma, Inc. (GTBP) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of GTBP?

The current price of GTBP is $5.51. Prices are updated in real time on Stocks360.

What is GTBP's price-to-earnings (PE) ratio?

GTBP's trailing twelve-month PE ratio is -0.05, based on current price and earnings per share data available on Stocks360.

What is GTBP's market capitalization?

GTBP's market capitalization is $6,954,480.00, placing it in the small-cap tier.

GT Biopharma, Inc. (GTBP)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$5.51

Market Cap

$6.95M

PE (TTM)

-0.05

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.85

Day Range

$5.32 – $5.69

52-wk Range

$4.91 – $28.75

Avg Volume

N/A

Volume

54.70K

GT Biopharma, Inc. (GTBP) is a publicly traded company in the Healthcare sector. Latest price: $5.51. Market cap $6.95M. Trailing PE -0.05. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-29 · $14.93 2026-10-28 · $5.51 (-63.09%)

Earnings

Most Recent

Aug 14, 2026

EPS $-3.00 vs est. $-2.00

Missed by $1.00

Next Earnings

Nov 13, 2026

EPS estimate $-2.50

Proprietary Signals

Signal snapshot temporarily unavailable.

About GT Biopharma, Inc.

GT Biopharma, Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and bringing to market novel immuno-oncology treatments. Their innovative approach centers on a proprietary technology platform called Tri-specific Killer Engager (TriKE) fusion proteins, which are designed to harness the body's immune cells. Central to their pipeline is GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate currently undergoing Phase I/II clinical trials. This therapeutic candidate is being evaluated for its potential in treating myelodysplastic syndromes, acute myeloid leukemia that has relapsed or proven refractory to prior treatments, advanced systemic mastocytosis, and other malignancies expressing CD33. The company's research also includes GTB-3650, which is in preclinical development targeting CD33 on myeloid leukemias, and GTB-5550, another preclinical asset aimed at solid tumors that are positive for B7-H3. GT Biopharma has forged key collaborations, including a co-development agreement with Altor BioScience Corporation for the clinical advancement of a 161533 TriKE fusion protein for various cancer indications. Furthermore, th…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.05×
P/S (TTM)	0.00×
P/B	2.40×
PEG	0.00×
P/FCF (TTM)	-0.48×
EV / EBITDA	-0.10×
EV / Sales	0.00×
Earnings Yield	-258.10%
Free Cash Flow Yield	-207.43%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	$1.99M
Net Income (TTM)	-$17.95M
Free Cash Flow (TTM)	-$14.30M
Net Debt	-$4.96M
Working Capital	$3.57M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-443.08%
Return on Invested Capital	-457.75%